From a medical standpoint, the fact that THC gets you high is an inconvenient truth. If it weren’t for this particular side effect that occurs when THC enters the bloodstream and brain, then the doses used could be much larger, and the pain relief and anti-inflammatory capabilities of the compound could be more fully unleashed.
The development of targeted delivery methods for cannabinoids is an increasingly valuable way of achieving optimal results, and is now being used for a growing list of medical conditions. In general, any method of focusing the delivery on the specific area that requires medical intervention while simultaneously reducing the levels of THC in the bloodstream would be significant to the medical profession. If particular joints or limbs are in pain, due to osteoarthritis, fibromyalgia, or related conditions, targeted delivery through topical patches or gels could potentially offer meaningful relief. Intestinal disorders could also be treated much more effectively if targeted directly. In fact, the list of conditions that could be treated is still growing as does the opportunity for focused treatment methods. A small amount of delivery of THC into the bloodstream, and to the brain, is still very well tolerated, but anything that enables higher local concentrations to be administered directly at the site of the disease can be considered beneficial.
The fact that medical marijuana is legalized now in more than half of the states of the U.S. (Ohio recently became the 26th state) is driving the way forward, as patients and doctors are educating themselves about the many possible therapeutic applications. It’s increasingly indicated for treating a very diverse array of diseases, including epilepsy, pain, multiple sclerosis, cancer, HIV/AIDs, and inflammatory bowel disease, including both Crohn’s disease and ulcerative colitis. Yet both patients and physicians are looking for more reliable and potent cannabinoid treatments that will make serious inroads against these disorders, and can be differentiated from the limited and sometimes crude options that are available today.
The potential is highly apparent, as studies have shown that cannabinoids can be far more potent than opiates for pain relief, and far more potent than aspirin or corticosteroids for providing anti-inflammatory effects. Specifically, cannabinoid drugs can be nearly 10 times as potent as opiates for pain relief, including morphine. Studies have also shown they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation.
But currently, the “elephant in the room” remains, which is that the desired potent effects cannot be achieved when high doses of THC enter the bloodstream and brain. Patients are forced to limit their doses, so targeted administration is critical. Our solution goes to the heart of this issue and offers an alternative means to increase the beneficial dosage, right at the site of disease – where it matters most, and relegates the psychoactive nature of the drug to a manageable side effect.
Here at Vitality, we have created proprietary drug compounds we call cannabosides that already hold great potential to solve this problem for the relief and potential cure of many intestinal conditions, which obviously can’t be targeted by lotions or creams. Our compounds take advantage of a targeted-release mechanism where microbial enzymes present in the intestines will enable a very site-specific localized release of compounds including THC, CBD, and many of the other known cannabinoids. Because of this, we could provide targeted relief of inflammatory bowel diseases (IBD) such as Crohn’s disease or ulcerative colitis, simply by enabling larger doses of cannabinoids to be delivered.
Our team is very excited, considering that non-targeted delivery of cannabinoids has already delivered significant benefits, including in placebo-controlled clinical studies. In these clinical studies, approximately 84% of patients with IBD had improvements in abdominal pain, and 77% had improvements in abdominal cramping. In a small Crohn’s disease study, 45% of patients entered into remission after 8 weeks of treatment. Delivering these same benefits and more through targeted delivery at the site of disease seems an approach destined for success, and a method that could make a lasting impact on how IBD is treated by physicians.
The Vitality team is now de-risking key aspects of this drug development program in preclinical studies and mapping out a path to demonstrating proof of their effectiveness in clinical trials. Please don’t hesitate to contact us to find out more, or connect with us on social media through Twitter, Facebook, or LinkedIn.
Robert Brooke, CEO
Notice Regarding Forward-Looking Statements
This document contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this document which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the online publication date of this document, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this document are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.